First Time Loading...

Tandem Diabetes Care Inc
NASDAQ:TNDM

Watchlist Manager
Tandem Diabetes Care Inc Logo
Tandem Diabetes Care Inc
NASDAQ:TNDM
Watchlist
Price: 32.1 USD 0.75%
Updated: Apr 16, 2024

Intrinsic Value

TNDM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. [ Read More ]

The intrinsic value of one TNDM stock under the Base Case scenario is 47.52 USD. Compared to the current market price of 32.1 USD, Tandem Diabetes Care Inc is Undervalued by 32%.

Key Points:
TNDM Intrinsic Value
Base Case
47.52 USD
Undervaluation 32%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Tandem Diabetes Care Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TNDM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Tandem Diabetes Care Inc

Provide an overview of the primary business activities
of Tandem Diabetes Care Inc.

What unique competitive advantages
does Tandem Diabetes Care Inc hold over its rivals?

What risks and challenges
does Tandem Diabetes Care Inc face in the near future?

Has there been any significant insider trading activity
in Tandem Diabetes Care Inc recently?

Summarize the latest earnings call
of Tandem Diabetes Care Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Tandem Diabetes Care Inc.

Provide P/S
for Tandem Diabetes Care Inc.

Provide P/E
for Tandem Diabetes Care Inc.

Provide P/OCF
for Tandem Diabetes Care Inc.

Provide P/FCFE
for Tandem Diabetes Care Inc.

Provide P/B
for Tandem Diabetes Care Inc.

Provide EV/S
for Tandem Diabetes Care Inc.

Provide EV/GP
for Tandem Diabetes Care Inc.

Provide EV/EBITDA
for Tandem Diabetes Care Inc.

Provide EV/EBIT
for Tandem Diabetes Care Inc.

Provide EV/OCF
for Tandem Diabetes Care Inc.

Provide EV/FCFF
for Tandem Diabetes Care Inc.

Provide EV/IC
for Tandem Diabetes Care Inc.

Show me price targets
for Tandem Diabetes Care Inc made by professional analysts.

What are the Revenue projections
for Tandem Diabetes Care Inc?

How accurate were the past Revenue estimates
for Tandem Diabetes Care Inc?

What are the Net Income projections
for Tandem Diabetes Care Inc?

How accurate were the past Net Income estimates
for Tandem Diabetes Care Inc?

What are the EPS projections
for Tandem Diabetes Care Inc?

How accurate were the past EPS estimates
for Tandem Diabetes Care Inc?

What are the EBIT projections
for Tandem Diabetes Care Inc?

How accurate were the past EBIT estimates
for Tandem Diabetes Care Inc?

Compare the revenue forecasts
for Tandem Diabetes Care Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Tandem Diabetes Care Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Tandem Diabetes Care Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Tandem Diabetes Care Inc compared to its peers.

Compare the P/E ratios
of Tandem Diabetes Care Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Tandem Diabetes Care Inc with its peers.

Analyze the financial leverage
of Tandem Diabetes Care Inc compared to its main competitors.

Show all profitability ratios
for Tandem Diabetes Care Inc.

Provide ROE
for Tandem Diabetes Care Inc.

Provide ROA
for Tandem Diabetes Care Inc.

Provide ROIC
for Tandem Diabetes Care Inc.

Provide ROCE
for Tandem Diabetes Care Inc.

Provide Gross Margin
for Tandem Diabetes Care Inc.

Provide Operating Margin
for Tandem Diabetes Care Inc.

Provide Net Margin
for Tandem Diabetes Care Inc.

Provide FCF Margin
for Tandem Diabetes Care Inc.

Show all solvency ratios
for Tandem Diabetes Care Inc.

Provide D/E Ratio
for Tandem Diabetes Care Inc.

Provide D/A Ratio
for Tandem Diabetes Care Inc.

Provide Interest Coverage Ratio
for Tandem Diabetes Care Inc.

Provide Altman Z-Score Ratio
for Tandem Diabetes Care Inc.

Provide Quick Ratio
for Tandem Diabetes Care Inc.

Provide Current Ratio
for Tandem Diabetes Care Inc.

Provide Cash Ratio
for Tandem Diabetes Care Inc.

What is the historical Revenue growth
over the last 5 years for Tandem Diabetes Care Inc?

What is the historical Net Income growth
over the last 5 years for Tandem Diabetes Care Inc?

What is the current Free Cash Flow
of Tandem Diabetes Care Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Tandem Diabetes Care Inc

Current Assets 748m
Cash & Short-Term Investments 467.9m
Receivables 105.6m
Other Current Assets 174.5m
Non-Current Assets 204.7m
PP&E 164.3m
Intangibles 2.8m
Other Non-Current Assets 37.6m
Current Liabilities 195.3m
Accounts Payable 49.6m
Accrued Liabilities 73.2m
Other Current Liabilities 72.5m
Non-Current Liabilities 443.8m
Long-Term Debt 285m
Other Non-Current Liabilities 158.7m
Efficiency

Earnings Waterfall
Tandem Diabetes Care Inc

Revenue
747.7m USD
Cost of Revenue
-380m USD
Gross Profit
367.7m USD
Operating Expenses
-600.9m USD
Operating Income
-233.2m USD
Other Expenses
10.6m USD
Net Income
-222.6m USD

Free Cash Flow Analysis
Tandem Diabetes Care Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TNDM Profitability Score
Profitability Due Diligence

Tandem Diabetes Care Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Negative Free Cash Flow
26/100
Profitability
Score

Tandem Diabetes Care Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

TNDM Solvency Score
Solvency Due Diligence

Tandem Diabetes Care Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
41/100
Solvency
Score

Tandem Diabetes Care Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNDM Price Targets Summary
Tandem Diabetes Care Inc

Wall Street analysts forecast TNDM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNDM is 36.11 USD with a low forecast of 18.18 USD and a high forecast of 63 USD.

Lowest
Price Target
18.18 USD
43% Downside
Average
Price Target
36.11 USD
12% Upside
Highest
Price Target
63 USD
96% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TNDM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TNDM Price
Tandem Diabetes Care Inc

1M 1M
+3%
6M 6M
+82%
1Y 1Y
-23%
3Y 3Y
-65%
5Y 5Y
-48%
10Y 10Y
-80%
Annual Price Range
32.1
52w Low
14.28
52w High
41.76
Price Metrics
Average Annual Return 10.89%
Standard Deviation of Annual Returns 61.08%
Max Drawdown -91%
Shares Statistics
Market Capitalization 2.1B USD
Shares Outstanding 65 631 000
Percentage of Shares Shorted 15.86%

TNDM Return Decomposition
Main factors of price return

What is price return decomposition?

TNDM News

Other Videos

Company Profile

Tandem Diabetes Care Inc Logo
Tandem Diabetes Care Inc

Country

United States of America

Industry

Health Care

Market Cap

2.1B USD

Dividend Yield

0%

Description

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The firm's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.

Contact

CALIFORNIA
San Diego
11075 Roselle St
+18583666900.0
https://www.tandemdiabetes.com/

IPO

2013-11-13

Employees

2 000

Officers

President, CEO & Director
Mr. John F. Sheridan
Executive VP, CFO & Treasurer
Ms. Leigh A. Vosseller
Executive VP & Chief Administrative Officer
Ms. Susan M. Morrison
Transitional Advisor
Mr. David B. Berger Esq.
Executive Officer
Mr. Brian B. Hansen
Executive Vice President and Chief Strategy & Product Officer
Ms. Elizabeth Anne Gasser
Show More
Chief Technical Officer
Mr. Rick A. Carpenter
Chief Legal, Privacy & Compliance Officer and Secretary
Ms. Shannon M. Hansen
Chief Human Resources Officer
Mr. Tom Fox
Chief Medical Officer
Dr. Jordan Pinsker M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TNDM stock?

The intrinsic value of one TNDM stock under the Base Case scenario is 47.52 USD.

Is TNDM stock undervalued or overvalued?

Compared to the current market price of 32.1 USD, Tandem Diabetes Care Inc is Undervalued by 32%.